Reports
- 2022 ESG Report
-
Under the purpose of creating value across environmental, societal, and governance areas and disclosing ESG achievements to the stakeholders in a transparent manner, Samsung Biologics has issued the ESG report.
Through the report, we aim to share our annual performances and activities transparently, collect opinions from various stakeholders, and reflect such opinions in our business activities in a bid to enhance the effectiveness of our ESG management practices.
2022 ESG Report
Under the purpose of creating value across environmental, societal, and governance areas and disclosing ESG achievements to the stakeholders in a transparent manner, Samsung Biologics has issued the ESG report.
Through the report, we aim to share our annual performances and activities transparently, collect opinions from various stakeholders, and reflect such opinions in our business activities in a bid to enhance the effectiveness of our ESG management practices.
Through the report, we aim to share our annual performances and activities transparently, collect opinions from various stakeholders, and reflect such opinions in our business activities in a bid to enhance the effectiveness of our ESG management practices.
- Reporting Period
-
The report covers the period of January 1st, 2021 to December 31st, 2021, but may include significant events dating up to the first half of 2022. Quantitative data for the past three fiscal years from 2019 to 2021 (with some environmental data for four years from 2018 to 2021) has been provided to allow for trend analysis over time.
- Reporting Standards
-
This report was prepared in accordance with the Core option of the Global Reporting Initiative (GRI) standards, global reporting standards for sustainability management. It also used ISO 26000, UN Global Compact principles,
Framework, SASB information disclosure standards, and TCFD recommendations as references.
- Reporting Scope
-
This report covers the sustainability activities and performances of all domestic and international businesses. Financial data is based upon consolidated K-IFRS. In addition to financial information, non-financial information has followed our formal disclosure system and has been prepared in accordance with the fiscal year, and the data related to energy usage and greenhouse gas emissions were prepared in accordance with the results of the emission verification.
2022 TCFD Report
-
-
2022 TCFD Report
Samsung Biologics has issued our first report 2022 aligned to the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD). As a leading sustainable CDMO partner, we understand the seriousness of climate change and its impact on public health; therefore, we are stepping up to the challenge of leading our industry towards a sustainable future.
Through the TCFD report, we aim to transparently disclose climate-related financial risks, opportunities and business strategies, and provide more decision-useful information to various stakeholders.
- Reporting Period
-
This report includes information from January 1, 2021 to December 31, 2021 according to the CDP reporting standards and fiscal year standards. Some important information in the second half of 2022 is also included. Quantitative data is based on four-year data from 2018 to 2021 for annual comparison.
- Reporting Standards
-
This report is written in accordance with the TCFD recommendation.
- Reporting Scope
-
Emissions across the entire scope from Samsung Biologics Upstream to Downstream process is calculated according to the CDP standards. Samsung Bioepis, a subsidiary of Samsung Biologics, is included as Scope 3 according to the 2021 consolidated basis. All financial and non-financial information, including Samsung Biologics’ entire climate-related performance is written based on the fiscal year according to the company’s disclosure system. Energy use-related data and Greenhouse Gas (GHG) emissions are written according to the third-party verification result.